8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Mar 16, 2026·SEC
Black Diamond Therapeutics, Inc.(BDTX)Earnings, Financials & Key Ratios
BDTX•NASDAQ
$1.84
4.7× P/E·Price updated Jul 2, 2026
AboutBlack Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$70M
- EBITDA$20M+125.7%
- Net Income$22M+132.1%
- EPS (Diluted)0.39+130.7%
- Gross Margin99.54%
- EBITDA Margin28.85%
- Operating Margin28.39%
- Net Margin31.95%
- ROE22.88%+132.8%
BDTX Price & Volume
Black Diamond Therapeutics, Inc. (BDTX) stock price & volume — 10-year historical chart
Loading chart...
Milestone Dependency Masks Persistent Clinical Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- Black Diamond Therapeutics remains a high-risk clinical-stage entity whose financial viability is tethered to sporadic, non-recurring milestone payments rather than a sustainable commercial engine.
- While the company achieved a singular $70M revenue inflow in 2025Q1, the absence of recurring top-line growth and a deepening accumulated deficit of $464.7M underscore the structural challenges of its R&D-heavy business model.
- Investors should monitor the narrowing cash runway, which dropped to $21M by 2025Q4, as the firm faces imminent liquidity constraints that may necessitate further dilutive financing to support ongoing clinical development.
Verdict Logic
the company's reliance on non-recurring revenue and a dwindling cash position of $21M as of 2025Q4 present significant risks of near-term dilution and liquidity shortfalls.
BDTX Growth Metrics
Black Diamond Therapeutics, Inc. (BDTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-948.77%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1366.67%
Return on Capital
10 Years-38.85%
5 Years-41.54%
3 Years-36.61%
Last Year17.33%
BDTX Recent Earnings
Black Diamond Therapeutics, Inc. (BDTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.16+11.1%
$0.18
Rev
—
$25M
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$0.14+22.2%
$0.18
Rev
—
$9M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.15+31.8%
$0.22
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.19+24.0%
$0.25
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.16vs $0.18+11.1% | —vs $25M |
| Q2 2026 | Mar 16, 2026 | $0.14vs $0.18+22.2% | —vs $9M |
| Q4 2025 | Nov 6, 2025 | $0.15vs $0.22+31.8% | — |
| Q3 2025 | Aug 7, 2025 | $0.19vs $0.25+24.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Black Diamond Therapeutics, Inc. (BDTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.84 | $105.44M | 4.72 | — | 31.95% | 22.88% | — | |
| $114.20 | $9.32B | -30.95 | -16.72% | -612.17% | -25.02% | — | |
| $123.60 | $9.09B | -21.13 | — | — | -42.78% | — | |
| $15.80 | $2.03B | 7.63 | 20.38% | 99.97% | 64.48% | — | |
| $17.92 | $5.57B | -40.73 | — | — | -77.01% | — | |
| $8.20 | $529.07M | -6.41 | -0.3% | -247.54% | -44.39% | — |
Compare BDTX vs Peers
Black Diamond Therapeutics, Inc. (BDTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BDTX SEC Filings & Documents
Black Diamond Therapeutics, Inc. (BDTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BDTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BDTX Frequently Asked Questions
Black Diamond Therapeutics, Inc. (BDTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Black Diamond Therapeutics, Inc.'s revenue?
Black Diamond Therapeutics, Inc. (BDTX) reported $70.0M in revenue for fiscal year 2025.
Is BDTX profitable?
Black Diamond Therapeutics, Inc. (BDTX) reported a net loss of $43.2M for fiscal year 2025.
Dividend & Returns
What is BDTX's return on equity?
Black Diamond Therapeutics, Inc. (BDTX) has a return on equity (ROE) of 22.9%. This is excellent, indicating efficient use of shareholder capital.
What is Black Diamond Therapeutics, Inc.'s free cash flow?
Black Diamond Therapeutics, Inc. (BDTX) had negative free cash flow of $34.0M in fiscal year 2025, likely due to heavy capital investments.